Rhythm’s third quarter results were driven by strong commercial momentum across both core Zio Monitor and Zio AT products, ...

iRhythm Technologies, a digital healthcare company specializing in cardiac telemetry products, received a warning letter from the FDA on May 25 detailing multiple issues with its Zio AT device. The ...

The market has left medical device stocks in the dust, but heart monitor maker iRhythm Technologies is proving an exception.

iRhythm Technologies Inc's (NASDAQ:IRTC) revenue of $124.1 million increased 21.6% Y/Y, beating the consensus of $120.34 million. The increase was driven by volume growth of Zio services, partially ...

Rhythm (Nasdaq: IRTC) announced a major regulatory submission alongside third-quarter results that came in ahead of the ...

SAN FRANCISCO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC) (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and ...

iRhythm Technologies, Inc. IRTC has received FDA 510(k) clearance for design changes and enhancements previously made to its Zio AT device. These modifications, submitted via letter to file, ensure ...

SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced initial research findings on post-market, real-world performance of Zio ® monitor, its ...

FDA clears iRhythm's first 510(k) submission for Zio AT device; second approval expected soon. Zio AT provides mobile cardiac telemetry for up to 14 days, aiding in ECG monitoring. Get more ...

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired iRhythm ...

Zio ATdevice, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients FDA 510 ...